Travere Therapeutics (TVTX) Institutional Ownership

During the previous two years, 141 institutional investors and hedge funds held shares of Travere Therapeutics. The most heavily invested institutionals were Deep Track Capital LP ($113.20M), RA Capital Management L.P. ($83.80M), Macquarie Group Ltd. ($74.79M), Armistice Capital LLC ($66.38M), Vanguard Group Inc. ($48.31M), State Street Corp ($38.29M), and Pictet Asset Management SA ($34.87M).Learn more on TVTX's institutional investors.

Of the 125 institutional investors that purchased Travere Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Assenagon Asset Management S.A. ($2.79M), Armistice Capital LLC ($1.36M), Avidity Partners Management LP ($1.32M), Healthcare of Ontario Pension Plan Trust Fund ($1.28M), Deep Track Capital LP ($1.22M), Vanguard Group Inc. ($1.21M), and Kynam Capital Management LP ($1.03M).

Institutional investors have bought a total of 24,055,156 shares in the last 24 months. This purchase volume represents approximately $325.49M in transactions.

Of the 57 institutional investors that sold Travere Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Saltoro Capital LP ($3.41M), Assenagon Asset Management S.A. ($2.34M), Renaissance Technologies LLC ($1.25M), Great Point Partners LLC ($943K), RA Capital Management L.P. ($938.26K), Jacobs Levy Equity Management Inc. ($892.98K), and State Street Corp ($773.98K).

Institutional investors have sold a total of 13,812,944 shares in the last 24 months. This volume of shares sold represents approximately $206.46M in transactions.